Back to Search Start Over

Writers, readers, and erasers RNA modifications and drug resistance in cancer.

Authors :
Chen, Di
Gu, Xinyu
Nurzat, Yeltai
Xu, Lixia
Li, Xueyuan
Wu, Lixin
Jiao, Henan
Gao, Peng
Zhu, Xuqiang
Yan, Dongming
Li, Shaohua
Xue, Chen
Source :
Molecular Cancer; 8/30/2024, Vol. 23 Issue 1, p1-33, 33p
Publication Year :
2024

Abstract

Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic alteration of gene expression via RNA modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), and adenosine-to-inosine (A-to-I) editing. These modifications are pivotal in regulating RNA splicing, translation, transport, degradation, and stability. Governed by "writers," "readers," and "erasers," RNA modifications impact numerous biological processes and cancer progression, including cell proliferation, stemness, autophagy, invasion, and apoptosis. Aberrant RNA modifications can lead to drug resistance and adverse outcomes in various cancers. Thus, targeting RNA modification regulators offers a promising strategy for overcoming drug resistance and enhancing treatment efficacy. This review consolidates recent research on the role of prevalent RNA modifications in cancer drug resistance, with a focus on m6A, m1A, m5C, m7G, Ψ, and A-to-I editing. Additionally, it examines the regulatory mechanisms of RNA modifications linked to drug resistance in cancer and underscores the existing limitations in this field. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14764598
Volume :
23
Issue :
1
Database :
Complementary Index
Journal :
Molecular Cancer
Publication Type :
Academic Journal
Accession number :
179358224
Full Text :
https://doi.org/10.1186/s12943-024-02089-6